CGEN Stock Overview
A clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Compugen Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.30 |
| 52 Week High | US$11.75 |
| 52 Week Low | US$2.36 |
| Beta | 2.65 |
| 11 Month Change | -15.56% |
| 3 Month Change | -29.91% |
| 1 Year Change | 121.29% |
| 33 Year Change | -63.52% |
| 5 Year Change | -74.37% |
| Change since IPO | -35.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| CGEN | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -10.5% | -2.8% | 0.8% |
| 1Y | 121.3% | -8.2% | 22.8% |
Return vs Industry: CGEN exceeded the IL Biotechs industry which returned -5.8% over the past year.
Return vs Market: CGEN exceeded the IL Market which returned 23% over the past year.
Price Volatility
| CGEN volatility | |
|---|---|
| CGEN Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IL Market | 7.3% |
| 10% least volatile stocks in IL Market | 2.9% |
Stable Share Price: CGEN's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: CGEN's weekly volatility has decreased from 24% to 7% over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 68 | Anat Cohen-Dayag | cgen.com |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
Compugen Ltd. Fundamentals Summary
| CGEN fundamental statistics | |
|---|---|
| Market cap | ₪475.30m |
| Earnings (TTM) | ₪5.94m |
| Revenue (TTM) | ₪222.18m |
81.2x
P/E Ratio2.2x
P/S RatioIs CGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEN income statement (TTM) | |
|---|---|
| Revenue | US$59.85m |
| Cost of Revenue | US$9.26m |
| Gross Profit | US$50.59m |
| Other Expenses | US$48.99m |
| Earnings | US$1.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.018 |
| Gross Margin | 84.53% |
| Net Profit Margin | 2.67% |
| Debt/Equity Ratio | 0% |
How did CGEN perform over the long term?
See historical performance and comparison